ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TCF Theracryf Plc

0.975
-0.025 (-2.50%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Theracryf Investors - TCF

Theracryf Investors - TCF

Share Name Share Symbol Market Stock Type
Theracryf Plc TCF London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-0.025 -2.50% 0.975 09:49:20
Open Price Low Price High Price Close Price Previous Close
1.00 0.975 1.00 0.975 1.00
more quote information »
Industry Sector
EQUITY INVESTMENT INSTRUMENTS

Top Investor Posts

Top Posts
Posted at 28/5/2024 08:22 by clocktower
TD - What you have top ask yourself, is why were certain investors happy to put up money at 1p a short time ago, as they would have had the full knowledge of what was expected.

I am waiting to see the buying kick in later.
Posted at 22/5/2024 12:03 by clocktower
Well peterm10, it has kick started a bit of buying, and does seem like a positive start to more company activity and possibly investor news on a more regular basis.

I also note they do still mention Stalicla in the RNS, although a small note,it remains.

I guess it might take a few more buys for it to tick up though but a little surprised, that after the more positive research note, and this RNS that the buying has not continued.
Posted at 10/5/2024 07:12 by terrydevlin1
I agree with your comment Clock Tower. It is incredibly disappointing to have no new deals signed up for SFX-01 since the Stalicla deal. There seems so little news now about SFX-01 in the past 10 months.
The sad reality is that TCF cannot afford to do their own trials so they cannot do much to prove the drug is effective and it seems like they cannot get anyone to trial it for them.
The Stalicla deal is so huge to TCF that they have no option but to wait for Stalicla to decide what they will do and when they will do it. It is TCF’s only potential income stream and money is running out. It is over a quarter of a year since the dispute was issued and no news at all. It doesn’t feel like there will be any news any time soon either.

I feel for all investors who invested as a result of the Stalicla deal announcement in 2022. At that time with £10m in the bank, Juvenesense having a deal with SFX-01 and milestone payments of up to $160m with Stalicla it seemed like this share had great potential. I wish I never had stumbled on that RNS.
Posted at 10/9/2012 12:38 by praipus
As you may know I track Laxeys holdings on the WAM thread and their number of BUY trades has definitiely reduced compared to the other active investors. And their number of SELL trades has increased!



If with all their resources researchers and analysts they can't make money what chance have us PI's got?
Posted at 31/1/2012 16:01 by wexboy
Hi folks,

Continuing my series on activist investors and other catalysts. Latest post highlights over a dozen listed activist funds/vehicles that you can invest in, including Terra Catalyst:



I hope you'll take a look (and plse don't hesitate to comment or email me).

Cheers,

Wexboy
Posted at 04/12/2009 10:52 by crawford
roundup,
the reason for investment here:

As at 30th September, 2009 the "look-through" NAV of TCF has been estimated to be 138 pence which represents a premium of 165% over the closing mark-to-market NAV at that date. The "look through" NAV of TCF's portfolio is calculated with reference to the NAVs of the underlying holdings, as opposed to the mark-to-market NAV which is calculated with reference to the share prices of the underlying holdings. Clearly the investment in Spazio accounts for a significant portion of the difference between the "look through" NAV and the mark-to-market NAV.
Over time, the Investment Manager will seek to capture the gap between the mark-to-market NAV and the "look-through" NAV by the use of a pro-active portfolio management strategy. Whilst investors should expect some further short term falls in the NAV of portfolio companies, the bulk of the downside pressure on NAVs now seems to have passed. Indeed, the Investment Manager has noted that NAVs are, for some UK and European property companies, now actually rising.
Posted at 04/12/2009 10:14 by mangal
roundup, do you mean the copy of interim report?
[edit:
If so, it's here
]
Posted at 04/11/2009 16:05 by crawford
Rugby Estates sells two industrial properties
11:53 | 04.11.09

By Laura Chesters

Rugby Estates has sold two industrial properties for £5m to clients of CBRE Investors as part of its planned disposals intended to return money to shareholders.

The properties, which were valued at £4.57m as at 31 July 2009, are located in Cranleigh in Surrey and Acton, in London.

Rugby said that the disposals were the latest step in the company's strategy to concentrate on its asset management business and to return capital to shareholders.

The company intends to return further capital to shareholders of not less than 40p a share within the next few months.

David Tye, chairman at Rugby, said: "The two fully let industrial properties were sold at a significant premium to the last reported valuation.

"The subsequent return of capital will bring the cumulative amount returned to shareholders since the announcement of this initiative in December 2008 to at least 102.5p a share currently issued ordinary share."



Read more:
Posted at 25/2/2008 17:52 by mangal
Floated today, 25Feb2008 - maybe worth tucking a few away if you believe the Commercial property market has bottomed.


Extract from 4 Dec 09 Intrims regarding NAV:

"As at 30th September, 2009 the "look-through" NAV of TCF has been estimated to be 138 pence which represents a premium of 165% over the closing mark-to-market NAV at that date. The "look through" NAV of TCF's portfolio is calculated with reference to the NAVs of the underlying holdings, as opposed to the mark-to-market NAV which is calculated with reference to the share prices of the underlying holdings. Clearly the investment in Spazio accounts for a significant portion of the difference between the "look through" NAV and the mark-to-market NAV."
....
"Investors should note that the investment in Spazio (which comprises over half the TCF portfolio) is currently held at the market price despite the very low free float of the company (less than 10%) following the bid which concluded on 13th July, 2009. If the board of Spazio decides at some point to delist the company, then the directors of Terra Catalyst Fund will have to decide what value should be attributed to the stake in the company. This may lead to periodic future adjustments to the stated NAVs (see section on Investment Carrying Values below). The NAV of Spazio was substantially in excess of the market price of the stock throughout the reporting period."

Your Recent History

Delayed Upgrade Clock